Abstract
Radiotherapy is the main treatment modality for prostate cancer. This study investigated the role of TGF-β1 in biological sequelae and tumor regrowth following irradiation, which are critical for the clinical radiation response of prostate cancer. Human and murine prostate cancer cell lines, and corresponding hormone-refractory (HR) cells, were used to examine the radiation response by clonogenic assays in vitro and tumor growth delay in vivo. Biological changes after irradiation, including cell death and tumor regrowth, were examined by experimental manipulation of TGF-β1 signaling. The correlations among tumor radiation responses, TGF-β1 levels, and regulatory T cells (Tregs) recruitment were also evaluated using animal experiments. HR prostate cancer cells appeared more radioresistant and had higher expression of TGF-β1 compared to hormone-sensitive (HS) cells. TGF-β1 expression was positively linked to irradiation and radioresistance, as demonstrated by in vitro and in vivo experiments. Inhibition of TGF-β1 increased tumor inhibition and DNA damage after irradiation. When mice were irradiated with a sub-lethal dose, the regrowth of irradiated tumors was significantly correlated with TGF-β1 levels and Tregs accumulation in vivo. Furthermore, blocking TGF-β1 clearly attenuated Tregs accumulation and tumor regrowth following treatment. These data demonstrate that TGF-β1 is important in determining the radiation response of prostate cancer, including tumor cell killing and the tumor microenvironment. Therefore, concurrent treatment with a TGF-β1 inhibitor is a potential therapeutic strategy for increasing the radiation response of prostate cancer, particularly for more aggressive or HR cancer cells.
Key message
• HR prostate cancer cells appeared more radioresistant and had higher expression of TGF-β1.
• TGF-β1 was positively linked to the radiation resistance of prostate cancer.
• Tumor regrowth following irradiation was significantly correlated with TGF-β1 and Tregs levels.
• Blocking TGF-β1 significantly attenuated RT-induced DNA repair and Tregs.
• TGF-β1 inhibitor increases the radiation response of HR cancer cells.
Similar content being viewed by others
References
Alongi F, De Bari B, Campostrini F, Arcangeli S, Matei DV, Lopci E, Petralia G, Bellomi M, Chiti A, Magrini SM et al (2013) Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review. Crit Rev Oncol Hematol 88:550–563
Wu CT, Chen WC, Liao SK, Hsu CL, Lee KD, Chen MF (2007) The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. Endocr Relat Cancer 14:633–643
Tombal B (2011) What is the pathophysiology of a hormone-resistant prostate tumour? Eur J Cancer 47(Suppl 3):S179–S188
Kuonen F, Secondini C, Ruegg C (2012) Molecular pathways: Emerging pathways mediating growth, invasion, and metastasis of tumors progressing in an irradiated microenvironment. Clin Cancer Res 18:5196–5202
Bernier J, Fuks Z (2004) Advances in translational radiation oncology: from molecular signaling to cancer cure. Int J Radiat Oncol Biol Phys 58:305–306
Atkinson MJ (2013) Radiation treatment effects on the proteome of the tumour microenvironment. Adv Exp Med Biol 990:49–60
Drabsch Y, ten Dijke P (2012) TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 31:553–568
Katsuno Y, Lamouille S, Derynck R (2013) TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25:76–84
Li MO, Flavell RA (2006) TGF-beta, T-cell tolerance and immunotherapy of autoimmune diseases and cancer. Expert Rev Clin Immunol 2:257–265
Fuxe J, Karlsson MC (2012) TGF-beta-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 22:455–461
Yang L (2010) TGFbeta and cancer metastasis: an inflammation link. Cancer Metastasis Rev 29:263–271
Saunier EF, Akhurst RJ (2006) TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 6:565–578
Oleinika K, Nibbs RJ, Graham GJ, Fraser AR (2013) Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 171:36–45
Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning SM, Barcellos-Hoff MH (2012) Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res 72:4119–4129
Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC et al (2011) TGFbeta1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 17:6754–6765
Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A (1998) Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37:19–29
Wu CT, Hsieh CC, Lin CC, Chen WC, Hong JH, Chen MF (2012) Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med (Berl) 90:1343–1355
Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4 + CD25+ regulatory T cells in patients with gastrointestinal malignancies: Possible involvement of regulatory T cells in disease progression. Cancer 98:1089–1099
Shiloh Y (2003) ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 3:155–168
Ewan KB, Henshall-Powell RL, Ravani SA, Pajares MJ, Arteaga C, Warters R, Akhurst RJ, Barcellos-Hoff MH (2002) Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res 62:5627–5631
Sak A, Stuschke M (2010) Use of gammaH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin Radiat Oncol 20:223–231
Sharma S, Sharma MC, Sarkar C (2005) Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology 46:481–489
Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454
Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C (2007) Tumor evasion of the immune system by converting CD4 + CD25− T cells into CD4 + CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178:2883–2892
Kachikwu EL, Iwamoto KS, Liao YP, DeMarco JJ, Agazaryan N, Economou JS, McBride WH, Schaue D (2011) Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys 81:1128–1135
Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, Pisa P (2006) CD4 + CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177:7398–7405
Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M (2013) High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer 49:1273–1279
Cretney E, Kallies A, Nutt SL (2013) Differentiation and function of Foxp3(+) effector regulatory T cells. Trends Immunol 34:74–80
Qinfeng S, Depu W, Xiaofeng Y, Shah W, Hongwei C, Yili W (2013) In situ observation of the effects of local irradiation on cytotoxic and regulatory T lymphocytes in cervical cancer tissue. Radiat Res 179:584–589
Tran DQ (2012) TGF-beta: the sword, the wand, and the shield of FOXP3(+) regulatory T cells. J Mol Cell Biol 4:29–37
Du S, Barcellos-Hoff MH (2013) Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor β activity in carcinomas. Semin Radiat Oncol 23:242–251
Muller WJ, Swanson I (2013) Orthotopic and Ectopic Models of Metastasis Experimental and Clinical Metastasis pp 227–236
Knox JD, Mack CF, Powell WC, Bowden GT, Nagle RB (1993) Prostate tumor cell invasion: a comparison of orthotopic and ectopic models. Invasion Metastasis 13:325–331
Elliott RL, Blobe GC (2005) Role of Transforming Growth Factor Beta in Human Cancer. J Clin Oncol 23:2078–2093
Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J (1995) Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med 1:282–284
Zavadova E, Vocka M, Spacek J, Konopasek B, Fucikova T, Petruzelka L (2014) Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy. Neoplasma 61:90–98
Reis ST, Pontes-Júnior J, Antunes AA, Sousa-Canavez JM, Abe DK, Cruz JA, Dall'oglio MF, Crippa A, Passerotti CC, Ribeiro-Filho LA et al (2011) Tgf-β1 expression as a biomarker of poor prognosis in prostate cancer. Clinics (Sao Paulo) 66:1143–1147
Shariat SF, Walz J, Roehrborn CG, Montorsi F, Jeldres C, Saad F, Karakiewicz PI (2008) Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. J Urol 179:1593–1597
Andarawewa KL, Costes SV, Fernandez-Garcia I, Chou WS, Ravani SA, Park H, Barcellos-Hoff MH (2011) Lack of radiation dose or quality dependence of epithelial-to-mesenchymal transition (EMT) mediated by transforming growth factor beta. Int J Radiat Oncol Biol Phys 79:1523–1531
Schaue D, Ratikan JA, Iwamoto KS, McBride WH (2012) Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83:1306–1310
Baba J, Watanabe S, Saida Y, Tanaka T, Miyabayashi T, Koshio J, Ichikawa K, Nozaki K, Koya T, Deguchi K et al (2012) Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 120:2417–2427
Lissoni P, Brivio F, Fumagalli L, Messina G, Meregalli S, Porro G, Rovelli F, Vigorè L, Tisi E, D'Amico G (2009) Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res 29:1847–1852
Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM (2003) Conversion of peripheral CD4 + CD25- naive T cells to CD4 + CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886
Nicolini A, Rossi G, Ferrari P, Carpi A (2014) Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer. Biomed Pharmacother 68:171–178
Smith AL, Robin TP, Ford HL (2012) Molecular pathways: Targeting the TGF-β pathway for cancer therapy. Clin Cancer Res 18:4514–4521
Competing interests
The author(s) indicated no potential conflict of interest.
Funding sources
The study was supported by National Science Council, Taiwan. Grant 101-2314-B-182-062-MY3,
Disclosure
The authors declare no conflict of interests related to this study.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(PDF 412 kb)
Rights and permissions
About this article
Cite this article
Wu, CT., Hsieh, CC., Yen, TC. et al. TGF-β1 mediates the radiation response of prostate cancer. J Mol Med 93, 73–82 (2015). https://doi.org/10.1007/s00109-014-1206-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-014-1206-6